These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 24689812)

  • 1. Pathogen reduction treatment using riboflavin and ultraviolet light impairs platelet reactivity toward specific agonists in vitro.
    Zeddies S; De Cuyper IM; van der Meer PF; Daal BB; de Korte D; Gutiérrez L; Thijssen-Timmer DC
    Transfusion; 2014 Sep; 54(9):2292-300. PubMed ID: 24689812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates.
    Perez-Pujol S; Tonda R; Lozano M; Fuste B; Lopez-Vilchez I; Galan AM; Li J; Goodrich R; Escolar G
    Transfusion; 2005 Jun; 45(6):911-9. PubMed ID: 15934989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology.
    Li J; Lockerbie O; de Korte D; Rice J; McLean R; Goodrich RP
    Transfusion; 2005 Jun; 45(6):920-6. PubMed ID: 15934990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of riboflavin and ultraviolet light treatment on platelet thrombus formation on collagen via integrin αIIbβ3 activation.
    Terada C; Mori J; Okazaki H; Satake M; Tadokoro K
    Transfusion; 2014 Jul; 54(7):1808-16. PubMed ID: 24506417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Riboflavin and UV light treatment of platelets: a protective effect of platelet additive solution?
    van der Meer PF; Bontekoe IJ; Daal BB; de Korte D
    Transfusion; 2015 Aug; 55(8):1900-8. PubMed ID: 25752624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell integrity and mitochondrial function after Mirasol-PRT treatment for pathogen reduction of apheresis-derived platelets: Results of a three-arm in vitro study.
    Picker SM; Steisel A; Gathof BS
    Transfus Apher Sci; 2009 Apr; 40(2):79-85. PubMed ID: 19233725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human platelets pathogen reduced with riboflavin and ultraviolet light do not cause acute lung injury in a two-event SCID mouse model.
    Chi X; Zhi L; Vostal JG
    Transfusion; 2014 Jan; 54(1):74-85. PubMed ID: 23656563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-time measurement of platelet shape change by light scattering under riboflavin and ultraviolet light treatment.
    Terada C; Shiba M; Satake M; Tadokoro K
    Transfusion; 2016 Mar; 56(3):587-95. PubMed ID: 26536611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro quality of single-donor platelets treated with riboflavin and ultraviolet light and stored in platelet storage medium for up to 8 days.
    Cookson P; Thomas S; Marschner S; Goodrich R; Cardigan R
    Transfusion; 2012 May; 52(5):983-94. PubMed ID: 22014032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units.
    Picker SM; Steisel A; Gathof BS
    Transfusion; 2008 Aug; 48(8):1685-92. PubMed ID: 18513255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of riboflavin and ultraviolet light treatment on platelet thrombus formation and thrombus stability on collagen.
    Terada C; Shiba M; Nagai T; Satake M
    Transfusion; 2017 Jul; 57(7):1772-1780. PubMed ID: 28417457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light-treated platelet concentrates.
    Ambruso DR; Thurman G; Marschner S; Goodrich RP
    Transfusion; 2009 Dec; 49(12):2631-6. PubMed ID: 19694996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Riboflavin and ultraviolet light treatment potentiates vasodilator-stimulated phosphoprotein Ser-239 phosphorylation in platelet concentrates during storage.
    Schubert P; Culibrk B; Coupland D; Scammell K; Gyongyossy-Issa M; Devine DV
    Transfusion; 2012 Feb; 52(2):397-408. PubMed ID: 21827504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogen reduction treatment of buffy coat platelet concentrates in additive solution induces proapoptotic signaling.
    Reid S; Johnson L; Woodland N; Marks DC
    Transfusion; 2012 Oct; 52(10):2094-103. PubMed ID: 22320126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology.
    Mirasol Clinical Evaluation Study Group
    Transfusion; 2010 Nov; 50(11):2362-75. PubMed ID: 20492615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogen-reduction.
    Picker SM; Oustianskaia L; Schneider V; Gathof BS
    Vox Sang; 2009 Jul; 97(1):26-33. PubMed ID: 19302416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Riboflavin and ultraviolet light treatment of platelets triggers p38MAPK signaling: inhibition significantly improves in vitro platelet quality after pathogen reduction treatment.
    Schubert P; Coupland D; Culibrk B; Goodrich RP; Devine DV
    Transfusion; 2013 Dec; 53(12):3164-73. PubMed ID: 23521225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flow cytometric assessment of agonist-induced P-selectin expression as a measure of platelet quality in stored platelet concentrates.
    Middelburg RA; Roest M; Ham J; Coccoris M; Zwaginga JJ; van der Meer PF
    Transfusion; 2013 Aug; 53(8):1780-7. PubMed ID: 23216254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell quality of apheresis-derived platelets treated with riboflavin-ultraviolet light after resuspension in platelet additive solution.
    Picker SM; Tauszig ME; Gathof BS
    Transfusion; 2012 Mar; 52(3):510-6. PubMed ID: 21981030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet derived cytokine accumulation in platelet concentrates treated for pathogen reduction.
    Tauszig ME; Picker SM; Gathof BS
    Transfus Apher Sci; 2012 Feb; 46(1):33-7. PubMed ID: 22119364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.